XML 72 R60.htm IDEA: XBRL DOCUMENT v3.21.2
Licenses and collaborative arrangement (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 13, 2021
$ / shares
shares
Jan. 31, 2021
USD ($)
Dec. 31, 2020
$ / shares
Jun. 30, 2019
Milestone
Dec. 31, 2017
Investors
Mar. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Milestone
Molecules
programs
$ / shares
Sep. 30, 2022
Jul. 31, 2021
USD ($)
$ / shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Common stock par value | $ / shares     $ 0.00006       $ 0.00006    
Issuance of ordinary shares in connection with collaboration and license arrangement           $ 62,250      
Number of molecules | Molecules             2    
Number of programs | programs             4    
Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Future milestone payments to be made upon achievement             $ 4,878,738    
Five Prime                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License agreement date         2017-12        
Payment of upfront fees             5,000    
Number of milestone payments | Investors         1        
Milestone payments             2,000    
Five Prime | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Additional milestone payments             37,000    
Deciphera Pharmaceuticals LLC                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License agreement date       2019-06          
Payment of upfront fees             20,000    
Milestone payment accrued           $ 12,000      
Number of milestone payments | Milestone       3          
Deciphera Pharmaceuticals LLC | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Additional milestone payments             173,000    
Argenx BV                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License agreement date   2021-01              
Development cost-sharing payment             75,000    
Issuance of ordinary shares in connection with collaboration and license arrangement, Shares | shares 568,182                
Common stock par value | $ / shares $ 0.00006                
Issuance of ordinary shares in connection with collaboration and license arrangement             62,250    
Future cash payment             25,000    
GSK                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Payment of upfront fees             15,000    
Milestone payment accrued             $ 3,500    
Number of milestone payments Accrued | Milestone             1    
Number of milestone payments | Milestone             1    
Milestone payments             $ 1,000    
Additional milestone payments             36,000,000    
ZLAB Turning Point Therapeutics Inc                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Milestone payment accrued             $ 3,000    
Number of milestone payments Accrued | Milestone             2    
Number of milestone payments | Milestone             1    
Milestone payments             $ 2,000    
Mirati Therapeutics Inc                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Payment of upfront fees for license agreement, accrued             65,000    
Future milestone payments to be made upon achievement             $ 273,000    
Mirati Therapeutics Inc | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Percentage of tiered royalties on annual net sales             20.00%    
Mirati Therapeutics Inc | Minimum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Percentage of tiered royalties on annual net sales               0.00%  
MacroGenics                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Payment of upfront fees             $ 25,000    
Payment of upfront fees for license agreement, accrued             $ 25,000    
Number of milestone payments | Milestone             2    
Milestone payments             $ 4,000    
Additional milestone payments             136,000    
Future milestone payments to be made upon achievement             $ 1,386,000    
MacroGenics | Collaboration and License Agreement [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Equity Method Investments                 $ 30,000
Issue price per share | $ / shares                 $ 31.30
Turning Point Therapeutics Inc                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License agreement date   2021-01         2020-07    
Payment of upfront fees   $ 25,000         $ 25,000    
Turning Point Therapeutics Inc | Potential Development Regulatory and Sales Based Milestone                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Additional milestone payments   $ 336,000              
Future milestone payments to be made upon achievement             146,000    
Cullinan Pearl Corp                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License agreement date     2020-12            
Payment of upfront fees             20,000    
Cullinan Pearl Corp | Potential Development Regulatory and Sales Based Milestone                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Future milestone payments to be made upon achievement             211,000    
Takeda Pharmaceutical Company Limited                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License agreement date     2020-12            
Payment of upfront fees             6,000    
Takeda Pharmaceutical Company Limited | Potential Development Regulatory and Sales Based Milestone                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Future milestone payments to be made upon achievement             $ 481,500